Committee for Medicinal Products for Human Use (CHMP): 11-14 September 2023, European Medicines Agency, Amsterdam, the Netherlands, from 11/09/2023 to 14/09/2023

Kevzara (sarilumab) supply shortage

Webinar on Regulatory Procedure Management for Product Lifecycle Management 1st roll-out on IRIS, Online, from 15/09/2023 to 15/09/2023

Human medicines European public assessment report (EPAR): Jardiance, empagliflozin, Diabetes Mellitus, Type 2;Heart Failure;Renal Insufficiency, Chronic, Date of authorisation: 22/05/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 30/06/2009, Revision: 23, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Brintellix,Vortioxetine, decision type: , therapeutic area: , PIP number: P/0337/2022

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Wet Macular Degeneration;Macular Edema;Diabetes Complications, Date of authorisation: 21/11/2012, Revision: 30, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Chloroprocaine hydrochloride, decision type: , therapeutic area: , PIP number: P/0334/2022

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Heart Failure, Date of authorisation: 26/05/2016, Revision: 18, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0352/2022